<DOC>
	<DOCNO>NCT02014272</DOCNO>
	<brief_summary>This bioequivalence study evaluate bioequivalence RIN 150 individual reference drug healthy volunteer .</brief_summary>
	<brief_title>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation , Rin 150 And Individual Reference Drugs In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Healthy male female , 21 55 year age , body weight less 55 kg , sign date informed consent document willing able comply schedule visit , treatment plan , laboratory test study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) , positive Hepatitis B surface antigen HIV serology result ; Pregnant nursing female ; History active tuberculosis ; Participated investigational drug study within 3 month ; Used prescription nonprescription drug within 7 day 5 halflives .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>RIN 150</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>